How do the long-term results of short implants compare with those of long implants placed after maxillary sinus augmentation? To get a clear look at the risks and benefits of each, researchers ...

Intersect ENT received CMS approval of a revised coding application for its Propel sinus implant, according to a Jan. 19 news release. Propel previously shared a billing code with Intersect ENT’s ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that ...

A synthetic biphasic calcium phosphate material proved as reliable after a year as deproteinized cow bone for sinus augmentation in a clinical implant trial reported online May 11 in Clinical Implant ...

Steroid-eluting implants inserted during or after sinus surgery may benefit patients with chronic sinusitis with or without nasal polyps, including those who can't tolerate oral steroids, a consensus ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced publication of a ...

Lower health care utilization was shown in patients with chronic rhinosinusitis, with and without nasal polyps, who had steroid-eluting implants vs those who did not in the 18 months following ...

Intersect ENT, Inc., a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced publication of a pooled analysis in the International Forum of Allergy ...

MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT®, Inc. (Nasdaq: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that the Centers ...

MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that ...